Can Stem Cell Therapy Help ACL Tears Heal Without Surgery?
For many years, patients with a torn anterior cruciate ligament, or ACL, were told that the ligament could not heal on its own and that reconstruction surgery was the only path back to sports, exercise, or an active lifestyle.
Today, that conversation is changing.
Emerging research suggests that the ACL may have a greater healing capacity than previously believed in some patients. At the same time, regenerative medicine treatments – including platelet-rich plasma (PRP), bone marrow aspirate concentrate (BMAC), and Wharton’s jelly-derived mesenchymal stem/stromal cells – are being studied for their potential to support the body’s healing response after ACL injury (2)(3).
This does not mean that every torn ACL can heal without surgery, or that biologic therapies have replaced ACL reconstruction. But it does mean that for selected patients, non-surgical and regenerative approaches may deserve a closer look as part of a comprehensive treatment strategy.
Understanding How an ACL May Heal
The traditional view of ACL injury has been that a completely torn ACL cannot heal because of the ligament’s limited blood supply and the challenging environment inside the knee joint.
However, published case reports and clinical observations have challenged that belief.
In one often-cited case, physicians reported on a 12-year-old boy who suffered a severe knee injury after being struck by a car. Because of the extent of his other injuries, ACL reconstruction was delayed. When surgeons later returned to begin the reconstruction process, they found that the ACL had regenerated to a degree that reconstruction was no longer needed (1). The authors suggested that protection of the healing tissue, bracing, and intra-articular scar formation may have contributed to the ligament’s recovery (1).
Cases like this are unusual, but they raise an important question: under the right conditions, can the body sometimes create a healing environment that allows the ACL to repair itself?
Researchers have proposed that in some injuries, the body may form a natural biologic scaffold from pooled blood and healing tissue. That scaffold may help support ligament repair in a way that was previously thought impossible. While this concept remains an evolving area of research, it has helped drive interest in biologic therapies designed to improve the healing environment inside the injured knee.
The Role of Biologic Therapies in ACL Injury Care
As understanding of ACL healing has expanded, researchers have increasingly focused on orthobiologic treatments that may support tissue repair. These treatments are designed not to mechanically replace the ligament, but to improve the local healing response.
A 2014 review on ACL injuries and stem cell therapy noted that the ACL may have some healing potential under intensive non-surgical rehabilitation conditions, and that biologic repair mechanisms involving progenitor cells and stem-cell-related pathways could help shape future treatment strategies (2).
More recent reviews have described a range of emerging biologic options for ACL injury management, including PRP, BMAC, exosomes, scaffolds, hydrogels, and stem-cell-based approaches (3). Among these, bone marrow aspirate concentrate, or BMAC, has drawn attention because it contains the patient’s own concentrated bone marrow cells, including signaling molecules and progenitor cells that may support healing and modulate inflammation (3).
The goal of these therapies is to create a more favorable regenerative environment in the knee – one that may help support tissue repair, reduce inflammation, and improve function during rehabilitation.
At the same time, it is important to keep the evidence in perspective. While these therapies are promising, current research does not show that stem cell treatment reliably replaces ACL reconstruction in all patients. The evidence is still evolving, and outcomes likely depend on factors such as tear location, severity, knee stability, associated injuries, timing of treatment, and commitment to rehabilitation (2)(3).
Return to Play Without ACL Reconstruction
Another important shift in ACL care is the growing recognition that not every patient requires immediate reconstruction surgery to return to a meaningful level of activity.
For selected patients, structured non-surgical management may allow a return to sport, work, or exercise without reconstruction. This approach typically focuses on reducing swelling, restoring range of motion, rebuilding strength, improving neuromuscular control, and gradually progressing back to activity under careful supervision (2)(3).
In other words, the question is no longer simply whether a torn ACL exists on MRI. The more important question may be whether the patient can regain enough stability, strength, function, and confidence to safely return to the activities that matter most.
That distinction is especially relevant in regenerative medicine. A patient does not necessarily need a “perfect” ligament appearance on imaging to do well clinically. In some cases, improved healing, improved symptom control, and improved functional stability may be enough to help the patient avoid or delay surgery.
Wharton’s Jelly Stem Cells and ACL Healing
One of the newer biologic therapies attracting attention in orthopedic and regenerative medicine is Wharton’s jelly, the gelatinous connective tissue found within the umbilical cord.
Wharton’s jelly contains mesenchymal stem/stromal cells and other biologically active components that researchers believe may help support tissue repair, regulate inflammation, and influence the healing environment within injured joints and soft tissues (3).
These cells are of interest because they appear to have several properties valued in regenerative medicine, including strong paracrine signaling, immunomodulatory effects, and the ability to interact with damaged tissue in ways that may support recovery (3).
In laboratory and preclinical studies, Wharton’s jelly-derived cells have shown promise in cartilage repair, inflammation control, and other orthopedic applications involving the knee (3).
However, this is where careful wording matters.
At this time, direct human clinical evidence for Wharton’s jelly stem cells specifically healing ACL tears remains limited. The current literature is more supportive of their broader regenerative potential in orthopedic medicine than of any claim that they have been proven to regenerate a torn ACL or replace ACL reconstruction surgery in a predictable way (3).
That means Wharton’s jelly is best described as a promising investigational regenerative option, not a proven stand-alone cure for ACL rupture.
For selected patients, Wharton’s jelly-based treatment may be considered as part of a larger non-surgical strategy that can include bracing, functional support, progressive rehabilitation, and careful monitoring of symptoms, stability, and return-to-activity goals.
Summary
Research into ACL healing has opened the door to new possibilities in sports medicine and regenerative care. PRP, BMAC, and Wharton’s jelly-derived regenerative products are all part of a growing effort to help the body heal more effectively after ligament injury (2)(3).
Still, responsible reporting matters.
The most accurate message today is not that stem cell therapy has replaced ACL reconstruction, but that regenerative medicine may expand treatment options for selected patients and may help support recovery as part of a comprehensive, individualized care plan (2)(3).
As research continues, biologic therapies may play an increasingly important role in helping patients reduce pain, improve function, and possibly avoid surgery in some cases. For now, the best outcomes are likely to come from careful diagnosis, proper patient selection, and a treatment program that combines regenerative strategies with high-quality rehabilitation.
References
1 Reported by Deren Bagsby, MD, George Gantsoudes, MD, and Robert Klitzman, MD Am J Orthop. 2015;44(8):E294-E297.
2 Hirzinger C, Tauber M, Korntner S, Quirchmayr M, Bauer HC, Traweger A, Tempfer H. ACL injuries and stem cell therapy. Archives of orthopaedic and trauma surgery. 2014 Nov;134(11):1573-8.
3 Yu X, Hu J, Li Y, Wen Y, Li B. ACL injury management: a comprehensive review of novel biotherapeutics. Frontiers in bioengineering and biotechnology. 2024 Nov 22;12:1455225.
The post Stem cell therapy for ACL tear | Non-surgical options appeared first on Stem Cell Institute.